Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18864182 | 1.00 | KDM4E (0.50) | KDM4ELMNAALDH1A1MAPTHPGD | |
| SCHEMBL18864183 | 1.00 | KDM4E (0.50) | KDM4ELMNAALDH1A1MAPTHPGD | |
| SCHEMBL18864174 | 1.00 | KDM4E (0.50) | KDM4ELMNAALDH1A1MAPTHPGD | |
| SCHEMBL18864177 | 1.00 | KDM4E (0.50) | KDM4ELMNAALDH1A1MAPTHPGD | |
| SCHEMBL18864179 | 1.00 | KDM4E (0.50) | KDM4ELMNAALDH1A1MAPTHPGD | |
| SCHEMBL18864180 | 1.00 | KDM4E (0.50) | KDM4ELMNAALDH1A1MAPTHPGD | |
| SCHEMBL18864170 | 1.00 | KDM4E (0.50) | KDM4ELMNAALDH1A1MAPTHPGD | |
| SCHEMBL18864181 | 0.99 | KDM4E (0.51) | KDM4ELMNAALDH1A1MAPTHPGD | |
| SCHEMBL14585956 | 0.84 | ALDH1A1 (0.48) | KDM4ELMNAALDH1A1MAPTHPGD | |
| Bicarbonate SCHEMBL10377652 | 0.84 | ALDH1A1 (0.67) | KDM4ELMNAALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087165-B2 | Fluoroquinolones and use thereof to treat bacterial infections | SORBONNE UNIVERSITE (FR) | 2018-10-02 | — | — | US | disclosed |
| US-20170144992-A1 | NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS | UNIVERSITÉ PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087165-B2 | Fluoroquinolones and use thereof to treat bacterial infections | CFTR, NQO2, FPR1 | KDM4E 3086/4885LMNA 2609/4885ALDH1A1 4095/4885 |
| US-20170144992-A1 | NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS | CFTR, IRF3, FPR1 | KDM4E 3242/4885LMNA 3107/4885ALDH1A1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.